An overall slump in securities class action litigation has continued in the first six months of 2014, according to a report from Cornerstone Research. But the outlook is less rosy for the biotech sector, which was hit with twice as many suits as in the two previous six-month periods.
‘Enforcement 40’ for 2020
Join Us On LinkedIn
Join the Securities Litigation and Enforcement Group on LinkedIn